• Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=14518029).
  

CLPUB00699
Romijn J.C., Erkens-Schulze S., van Weerden W.M., Teubel W.J., Trapman J., Schroder F.H.
Development and characterization of a new in vitro model to study the mechanisms of prostate cancer progression.
Urol. Res. 23:265.P81-265.P81(1995)

PubMed=11304728; DOI=10.1002/pros.1045
van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.
Widely used prostate carcinoma cell lines share common origins.
Prostate 47:36-51(2001)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

PubMed=14518030; DOI=10.1002/pros.10291
van Bokhoven A., Caires A., Di Maria M., Schulte A.P., Lucia M.S., Nordeen S.K., Miller G.J., Varella-Garcia M.
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines.
Prostate 57:226-244(2003)

CLPUB00698
van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands

PubMed=15900601; DOI=10.1002/ijc.21201
Marques R.B., Erkens-Schulze S., de Ridder C.M.A., Hermans K.G., Waltering K., Visakorpi T., Trapman J., Romijn J.C., van Weerden W.M., Jenster G.
Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment.
Int. J. Cancer 117:221-229(2005)

PubMed=20976069; DOI=10.1371/journal.pone.0013500; PMCID=PMC2957443
Marques R.B., Dits N.F., Erkens-Schulze S., van Weerden W.M., Jenster G.
Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.
PLoS ONE 5:E13500-E13500(2010)